Description
Pletal 100mg Tablets Online
Pletal tablets are used to treat intermittent claudication. The blockage of the blood vessels to the legs causes a distinctive type of pain called intermittent claudication. In this condition, which usually affects the calves, you experience muscle pain or cramping whenever you walk some distance, but the pain disappears when you rest. The pain occurs because the calf muscles are not receiving enough oxygen.
Order Pletal Tablet right now through our site dozeoutlet.com for hassle-free deliveries worldwide.
Pletal Tablets active ingredient: cilostazol reduces attacks of intermittent claudication that may occur after walking. (cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The empirical formula of cilostazol is butoxy-3,4-dihydro-2quinolinone, CAS-73963-72-1
Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH. And is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH. PLETAL (cilostazol) tablets for oral administration are available in 50 mg triangular and 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hydroxypropyl methylcellulose 2910, magnesium stearate, and microcrystalline cellulose.
PLETAL (cilostazol) tablets for oral administration are available in 50 mg triangular and 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hydroxypropyl methylcellulose 2910, magnesium stearate, and microcrystalline cellulose. The recommended dosage of PLETAL is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner. Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced. If symptoms are unimproved after 3 months, discontinue PLETAL.
Dose Reduction With CYP3A4 And CYP2C19 Inhibitors
PLETAL is only recommended for patients whose symptoms have not improved sufficiently after making lifestyle modifications (such as stopping smoking and increasing exercise) and after other appropriate interventions. It is important that you continue the modifications you have made to your lifestyle whilst taking cilostazol.
